ADCETRIS® for your suitable adult patients with Hodgkin lymphoma, systemic anaplastic large cell lymphoma, and cutaneous T-cell lymphoma¹

ADCETRIS is licensed for use in certain CD30+ lymphomas. The specific indications and funding criteria by NICE and SMC can be found by navigating to the disease-specific pages below:

ADCETRIS mechanism of action

ADCETRIS is an antibody drug conjugate which delivers the cytotoxic agent monomethyl auristatin E to CD30-expressing cells, inducing cell cycle arrest and apoptosis/ADCETRIS-brentuximab-vedotin/ctcl

ADCETRIS key safety information

Please consult the Summary of Product Characteristics before prescribing ADCETRIS and for full information about dosing, administration, contraindications, special warnings and tolerability profile.

When used as monotherapy, the most frequent adverse reactions (≥10%) were infections, peripheral sensory neuropathy, nausea, fatigue, diarrhoea, pyrexia, neutropenia, upper respiratory tract infection, arthralgia, rash, cough, vomiting, pruritus, peripheral motor neuropathy, infusion-related reactions, constipation, dyspnoea, myalgia, weight decreased, and abdominal pain.¹

When used in combination with chemotherapy, the most frequent adverse reactions (≥10%) were infections, neutropenia, peripheral sensory neuropathy, nausea, constipation, vomiting, diarrhoea, fatigue, pyrexia, alopecia, anaemia, weight decreased, stomatitis, febrile neutropenia, abdominal pain, decreased appetite, insomnia, bone pain, rash, cough, dyspnoea, arthralgia, myalgia, back pain, peripheral motor neuropathy, upper respiratory tract infection, and dizziness.¹

NICE, National Institute for Health and Care Excellence; SMC, Scottish Medicines Consortium.

1. ADCETRIS (brentuximab vedotin). Summary of Product Characteristics; 2. Deng C, et al. Clin Cancer Res 2013;19:22–27.